Monitoring Immune Responses After Glioma Vaccine Immunotherapy

Neurosurgery Clinics of North America

Volumn 21, Issue 1, 2010, Pages 195-199

  Jian, Brian ^a   Yang, Isaac ^a   Parsa, Andrew T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antigen; Clinical trials; Immune response; Immunomonitoring

Indexed keywords

CANCER VACCINE; CHROMIUM; CYTOKINE; MELANOMA VACCINE; PEPTIDE VACCINE; TUMOR CELL VACCINE;

ACCURACY; B LYMPHOCYTE; CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL ASSAY; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; GLIOBLASTOMA; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; IMMUNOSURVEILLANCE; LYMPHOCYTE FUNCTION; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; TARGET CELL DESTRUCTION;

ANIMALS; ANTIBODY FORMATION; BRAIN NEOPLASMS; CHROMIUM; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIOMA; HUMANS; IMMUNOTHERAPY; POPULATION SURVEILLANCE; T-LYMPHOCYTES;

EID: 70450185093     PISSN: 10423680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nec.2009.09.004     Document Type: Review

References (27)

1. Pardoll D., and Allison J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 10 (2004) 887-892
2. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 10 (2005) 987-996
3. Heimberger A.B., Archer G.E., Crotty L.E., et al. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 50 1 (2002) 158-164 [discussion: 164-6]
4. Heimberger A.B., Crotty L.E., Archer G.E., et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 9 11 (2003) 4247-4254
5. Liau L., Black K., Prins R., et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90 6 (1999) 1115-1124
6. Liau L., Fakhrai H., and Black K. Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene. Neurol Res 20 8 (1998) 742-747
7. Liau L.M., Jensen E.R., Kremen T.J., et al. Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination. Cancer Res 62 8 (2002) 2287-2293
8. Liau L.M., Prins R.M., Kiertscher S.M., et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11 15 (2005) 5515-5525
9. Parsa A.T., Waldron J.S., Panner A., et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13 1 (2007) 84-88
10. Prins R.M., Graf M.R., and Merchant R.E. Cytotoxic T cells infiltrating a glioma express an aberrant phenotype that is associated with decreased function and apoptosis. Cancer Immunol Immunother 50 6 (2001) 285-292
11. Sampson J.H., Akabani G., Archer G.E., et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 65 1 (2003) 27-35
12. Sampson J.H., Crotty L.E., Lee S., et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A 97 13 (2000) 7503-7508
13. Yang I., Kremen T.J., Giovannone A.J., et al. Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme. J Neurosurg 100 2 (2004) 310-319
14. Yu J.S., Liu G., Ying H., et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64 14 (2004) 4973-4979
15. Yu J.S., Wheeler C.J., Zeltzer P.M., et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61 3 (2001) 842-847
16. Galon J., Costes A., Sanchez-Cabo F., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 5795 (2006) 1960-1964
17. Fecci P.E., Mitchell D.A., Whitesides J.F., et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66 6 (2006) 3294-3302
18. Janetzki S., Panageas K.S., Ben-Porat L., et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 57 3 (2008) 303-315
19. Klinman D.M., and Nutman T.B. ELISPOT assay to detect cytokine-secreting murine and human cells. Curr Protoc Immunol (2001) Chapter 6: p. Unit 6 19
20. Brunner K.T., Mauel J., Cerottini J.C., et al. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 14 2 (1968) 181-196
21. Schmittel A., Keilholz U., Thiel E., et al. Quantification of tumor-specific T lymphocytes with the ELISPOT assay. J Immunother 23 3 (2000) 289-295
22. Korangy F., Ormandy L.A., Bleck J.S., et al. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 10 13 (2004) 4332-4341
23. Speiser D.E. Immunological techniques: ex vivo characterization of T cell-mediated immune responses in cancer. Curr Opin Immunol 17 4 (2005) 419-422
24. Speiser D.E., Cerottini J.C., and Romero P. Tumor cell recognition efficiency by T cells. PLoS Med 2 3 (2005) e77 author reply e95
25. Speiser D.E., and Romero P. Toward improved immunocompetence of adoptively transferred CD8+ T cells. J Clin Invest 115 6 (2005) 1467-1469
26. Dannull J., Su Z., Rizzieri D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 12 (2005) 3623-3633
27. Dannull J., Nair S., Su Z., et al. Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood 105 8 (2005) 3206-3213